Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.

ABSTRACT:

Purpose

Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor combination recently approved in Europe and the USA for the treatment of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), among other indications. In the phase III REPROVE trial (NCT01808092), ceftazidime-avibactam demonstrated non-inferiority to meropenem for the treatment of patients with nosocomial pneumonia (NP), including VAP. As ceftazidime-avibactam was not studied in patients with NP prior to REPROVE, selecting an appropriate dosage regimen in the "perfect storm" of NP required careful consideration of potential determinants and confounders of response specific to the NP patient population.

Methods

This review describes the series of preclinical studies and

SUBMITTER: Das S 

PROVIDER: S-EPMC7223046 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature